Bluebird Bio, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Bluebird Bio is asking stockholders to vote for a reverse stock split to maintain Nasdaq compliance and enable future financing, crucial for reaching cash flow breakeven in the second half of 2025.
Bluebird Bio adjourned its annual meeting to solicit additional votes for a reverse stock split proposal aimed at maintaining Nasdaq listing and securing future financing.
Bluebird Bio is urging its stockholders to vote in favor of a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement and enable the company to raise additional capital.
Bluebird Bio is urging stockholders to vote in favor of Proposals 4 and 5, including a reverse stock split and an amendment to the incentive award plan, at the Annual Meeting of Stockholders on November 6, 2024.
Bluebird Bio is addressing a potential delisting from the Nasdaq Global Select Market due to its stock price falling below the minimum bid price requirement and is considering a reverse stock split.
Bluebird Bio has filed a definitive proxy statement with the SEC, indicating upcoming shareholder meetings and voting on key corporate matters.
Bluebird Bio is asking stockholders to vote on proposals including officer exculpation, a reverse stock split, and amendments to its incentive award plan at the upcoming annual meeting.